Table 2 Clinical characteristics of cytological melanoma samples and relation with HOXC13 expression
From: Increased HOX C13 expression in metastatic melanoma progression
HOX C13 Score | 0 | 1 | 2 | 3 | Sample N° |
|---|---|---|---|---|---|
Sex N° |  |  |  |  |  |
Male | 1 (9,1%) | 1 (9,1%) | 5 (45,5%) | 4 (36,4%) | 20 |
Female | 0 (0%) | 2 (22,2%) | 2 (22,2%) | 5 (55,6%) | Â |
Age | Â | Â | Â | Â | Â |
<60 | 0 (0%) | 2 (22,2%) | 3 (33,3%) | 4 (44,4%) | 20 |
>60 | 1 (9,1%) | 1 (9,1%) | 4 (36,4%) | 5 (45,5%) | Â |
pT | Â | Â | Â | Â | Â |
I | 0 (0%) | 0 (0%) | 1(100%) | 0(0%) | 20 |
II | 0 (0%) | 0 (0%) | 0 (0%) | 5 (100%) | Â |
III | 1 (14,3%) | 1 (14,3%) | 3 (42,9%) | 2 (28,6%) | Â |
IV | 0 (0%) | 2 (28,6%) | 3 (42,9%) | 2 (28,6%) | Â |
Lymph node localization | Â | Â | Â | Â | |
axillary | 1 (11,1%) | 0 (0%) | 4 (44,4%) | 4 (44,4%) | 20 |
inguinal | 0 (0%) | 2 (28,6%) | 2 (28,6%) | 3 (42,9%) | Â |
iliac region | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) | Â |
scapulary | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | Â |
supraclavicular | 0 (0%) | 0 (0%) | 1 (50%) | 1 (50%) | Â |